Drug Development for Schizophrenia
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropharmacology and Neuropathology".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 77
Special Issue Editor
Interests: multiple chemical sensitivity; anxiety; depression; new psychoactive substances; NPS; suicide; suicidality; synthetic cannabinoids; synthetic cathinones; new synthetic opioids; ketamine; esketamine; s-ketamine; obsessive–compulsive disorder (OCD); substance use disorder; drug misuse; drug abuse; drug diversion; Psychosis; substance-induced-psychosis
Special Issue Information
Dear Colleagues,
Schizophrenia is a severe and complex psychiatric disorder that affects millions of individuals worldwide. Despite significant progress in understanding its pathophysiology, the development of effective pharmacological treatments remains a critical challenge. Current antipsychotic medications primarily target dopaminergic pathways and often fail to address the full spectrum of symptoms, including cognitive deficits and negative symptoms, while also being associated with significant side effects.
This Special Issue of Brain Sciences aims to present cutting-edge research on drug development for schizophrenia. We invite authors to contribute original research articles and reviews covering a broad range of topics, including but not limited to the following: novel pharmacological targets, advancements in antipsychotic drug mechanisms, personalized medicine approaches, drug repurposing strategies, biomarkers for treatment response, neuroinflammatory and neurodevelopmental perspectives, innovative drug delivery systems, computational drug discovery, and the role of emerging compounds in schizophrenia treatment. Special emphasis will be placed on translational research that bridges the gap between basic neuroscience and clinical applications.
By gathering the latest advancements in drug development for schizophrenia, this Special Issue aims to provide insights that will enhance future therapeutic strategies and improve patient outcomes.
Dr. Alessio Mosca
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antipsychotics
- biomarkers
- glutamatergic modulation
- schizophrenia treatment
- drug discovery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
